ArticleScientific reports2017
D-Cateslytin, a new antimicrobial peptide with therapeutic potential.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 35 citations in OpenAlex.
- Comparative antioxidant efficacy of D-Cateslytin combined with modified triple antibiotic paste and calcium hydroxide: anFrontiers in dental medicine · 2026Article
- Evaluation of antimicrobial and antibiofilm efficacy of different antimicrobial peptides on multispecies biofilm of endodontic pathogens.Journal of conservative dentistry and endodontics · 2025Article
- How Unnatural Amino Acids in Antimicrobial Peptides Change Interactions with Lipid Model Membranes.The journal of physical chemistry. B · 2024Article
- The Editorial Position on 'Recent Advances in Multifunctional Antimicrobial Peptides as Preclinical Therapeutic Studies and Clinical Future Applications'.Pharmaceutics · 2023Article
- Catestatin: Antimicrobial Functions and Potential Therapeutics.Pharmaceutics · 2023Review
- Antimicrobial Proteins: Structure, Molecular Action, and Therapeutic Potential.Pharmaceutics · 2022Review
- The dual antimicrobial and immunomodulatory roles of host defense peptides and their applications in animal production.Journal of animal science and biotechnology · 2022Review
- Chromogranin A and Its Fragments in the Critically Ill: An Expanding Domain of Interest for Better Care.Pharmaceutics · 2022Review
- Antimicrobial Peptides with Anti-International journal of molecular sciences · 2022Review
- The Catestatin-Derived Peptides Are New Actors to Fight the Development of Oral Candidosis.International journal of molecular sciences · 2022Article
- The antimicrobial peptides secreted by the chromaffin cells of the adrenal medulla link the neuroendocrine and immune systems: From basic to clinical studies.Frontiers in immunology · 2022Review
- Antimicrobial Peptides and Their Applications in Biomedical Sector.Antibiotics (Basel, Switzerland) · 2021Review
- Catestatin in innate immunity and Cateslytin-derived peptides against superbugs.Scientific reports · 2021Article
- Antimicrobial peptides - Advances in development of therapeutic applications.Life sciences · 2020Review
- Self-defensive antimicrobial biomaterial surfaces.Colloids and surfaces. B, Biointerfaces · 2020Article
- D- and Unnatural Amino Acid Substituted Antimicrobial Peptides With Improved Proteolytic Resistance and Their Proteolytic Degradation Characteristics.Frontiers in microbiology · 2020Article
- The Analogs of Temporin-GHa Exhibit a Broader Spectrum of Antimicrobial Activity and a Stronger Antibiofilm Potential againstMolecules (Basel, Switzerland) · 2019Article
- D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of antimicrobial resistant microorganisms constitutes an increasingly serious threat to global public health. As a consequence, the efficacy of conventional antimicrobials is rapidly declining, threatening the ability of healthcare professionals to cure common infections. Over the last two decades host defense peptides have been identified as an attractive source of new antimicrobials. In the present study, we characterized the antibacterial and mechanistic properties of D-Cateslytin (D-Ctl), a new epipeptide derived from L-Cateslytin, where all L-amino acids were replaced by D-amino acids. We demonstrated that D-Ctl emerges as a potent, safe and robust peptide antimicrobial with undetectable susceptibility to resistance. Using Escherichia coli as a model, we reveal that D-Ctl targets the bacterial cell wall leading to the permeabilization of the membrane and the death of the bacteria. Overall, D-Ctl offers many assets that make it an attractive candidate for the biopharmaceutical development of new antimicrobials either as a single therapy or as a combination therapy as D-Ctl also has the remarkable property to potentiate several antimicrobials of reference such as cefotaxime, amoxicillin and methicillin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.